Please login to the form below

Not currently logged in
Email:
Password:

Unlicensed sex drugs seized by MHRA

Enforcement officers from the UK's Medicines and Healthcare products Regulatory Agency seize nearly USD 709,263 worth of unlicensed medicines

Enforcement officers from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) have seized nearly GBP 350,000 (USD 709,263) worth of unlicensed medicines.

The drugs were discovered on 1 August 2007 at a secure lock-up facility in Uxbridge, West London and included Kamagra tablets and sachets, Lovegra and Apcalis, which are manufactured in India, but are unlicensed and untested despite claiming to treat male impotence. Investigations are ongoing.

Danny Lee-Frost, MHRA's head of criminal operations, said: ìThe type of medicines we seized cannot be guaranteed to be acceptably safe because they have not gone through the correct licensing regulatory process. At best these medicines could be a waste of money, at worst they could be severely detrimental to your health.î

If an individual is convicted of offences under the Medicines Act 1968, they can be sentenced to a maximum of two years imprisonment and/ or an unlimited fine. Where appropriate the MHRA will use the Proceeds of Crime Act 2002 to determine whether or not benefits were accrued through criminal activity and will recoup illicit earnings if the individual is found guilty.

7th August 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cogora

Cogora has been a leader in healthcare publishing for over 30 years and has become one of the leading full-service...

Latest intelligence

Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...

Infographics